National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dimethyl fumarate (Tecfidera®is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (MS).

Rapid Review

Commenced Completed Outcome
04/02/2014 06/03/2014 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
16/07/2014  14/01/2015 Reimbursement not recommended

14/01/2015

Following NCPE assessment of the company submission, dimethyl fumarate (Tecfidera®) is not considered cost-effective for the treatment of adult patients with relapsing remitting MS and therefore is not recommended for reimbursement at the submitted price.

Summary

14/04/2015

Following pricing negotiation, the HSE has approved reimbursement of Tecfidera® under the High Tech Drugs Scheme.